Search Results for "Is Gist Hereditary"
Original Source: Hereditary and non-hereditary syndromic gastointestinal stromal tumours.
The majority of gastrointestinal stromal tumours (GISTs) present as solitary gastrointestinal masses in adults aged 50-70 years. A small subset of GISTs (≤5%) occurs in the setting of familial or idiopathic multitumour syndrome. In decreasing order of frequency, neurofibromatosis Recklinghausen (NF-1), Carney triad (gastric GIST, pulmonary chondroma and extra-adrenal paraganglioma), familial GIST syndromes resulting from germline mutations in c-Kit/PDGFRA and the Carney-Stratakis syndrome (hereditary GIS...
Matching Channels
Matching News
Regorafenib May Expand GIST Treatment Options
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III...
Stivarga Approved By FDA For Advanced Gastrointestinal Stromal Tumors (GIST)
Stivarga (regorafenib), a cancer medication, has had its usage expanded to include patients suffering from advanced gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration. The...
Surgery Is Beneficial Even When GIST Responds to Imatinib
Patients with metastatic or recurrent gastrointestinal stromal tumors (GIST) had better survival when surgery was added to imatinib treatment. Medscape Medical News
Strong Case for Regorafenib in GIST, Not Colorectal Cancer
Clinical data supporting the use of regorafenib in gastrointestinal stromal tumors (GIST) and in colorectal cancer have now been published. Medscape Medical News
FDA Oks Bayer's Stivarga for GIST
(MedPage Today) -- Regorafenib (Stivarga), a multi-kinase inhibitor that blocks several cancer growth enzymes, has been approved to treat advanced gastrointestinal stromal tumors (GIST) that no longer...
Bayer files for second regorafenib use in Japan, GIST
Bayer is wasting no time in expanding the planned indications for regorafenib in Japan, filing an approval application for use in metastatic and/or unresectable gastrointestinal stromal tumors (GIST)...
Bowel cancer and GIST patients could benefit from novel oral drug
Two phase 3 trials, published in The Lancet, have shown that a novel oral drug called regorafenib could offer survival benefits to people with bowel (colorectal) cancer or gastrointestinal stromal tum...
Bayer/Onyx win US FDA OK to expand Stivarga in GIST
Bayer HealthCare and its partner Onyx Pharmaceuticals won the US FDA's blessing to expand the labeling for Stivarga (regorafenib) as a treatment for patients with locally advanced, unresectable or...
Matching PubMed Articles
Hereditary and non-hereditary syndromic gastointestinal stromal tumours.
The majority of gastrointestinal stromal tumours (GISTs) present as solitary gastrointestinal masses in adults aged 50-70 years. A small subset of GISTs (≤5%) occurs in the setting of familial or i...
Occurrence of other tumors in patients with GIST.
OBJECTIVE: Evaluate the presence of other tumors in cohort of patients with GIST treated at a cancer treatment referral center - INCA. METHODS: We reviewed the medical records of patients diagnosed wi...
Adjuvant treatment of GIST: patient selection and treatment strategies.
Tyrosine kinase inhibitors that target the key molecular drivers of gastrointestinal stromal tumour (GIST) are effective treatments of advanced-stage GIST. Yet, most of these patients succumb to the d...
Synchronous Tumors: Adenosquamous Carcinoma of Pancreas and GIST of Stomach.
We report herein a unique case of an adenosquamous carcinoma (ASC) of the pancreas and a synchronous gastrointestinal stromal tumor (GIST) of stomach in a 75-year-old Caucasian male. He presented with...
DOG1 utility in diagnosing gastrointestinal stromal tumors on fine-needle aspiration.
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract, and the majority contain KIT or PDGFRA activating mutations. Fine-needle aspiration bi...
